Coronavirus

Markets

Novavax stock tanks on report of COVID-19 vaccine manufacturing troubles

The potential production problems with Novavax's vaccine could hamper the efforts of the COVAX initiative, which forecast in September that it will be able to provide low and middle-income countries 1.425 billion COVID-19 vaccine doses to by the end of the year and 2 billion doses by the first quarter of 2022.

Politics

FDA delays Moderna for adolescents to review rare side effect

The Food and Drug Administration is delaying a decision on authorizing Moderna Inc.’s MRNA -1.69% COVID-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of a rare inflammatory heart condition, according to people familiar with the matter.